SIMILAR PATTERN OF AMINO ACIDS MAPPED TO 'BZ7'


List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)
Filter list by:
DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 Interface HETATM RMSD Dali
Z-score		 Seq.
Identity (%)		 View Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_2_BO221405_1
(PROTEASOME COMPONENT
PRE3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 11 THR C   1
ALA C  28
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.4A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.05A 2f162-6avoC:
29.2		 2f162-6avoC:
21.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_2_BO221405_1
(PROTEASOME COMPONENT
PRE3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 11 THR C   1
LYS C  33
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.64A 2f162-6avoC:
29.2		 2f162-6avoC:
21.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F16_K_BO2K1402_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		7 / 10 THR C   1
ALA C  20
ALA C  22
VAL C  31
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.59A 2f16K-6avoC:
24.6
2f16L-6avoC:
24.8		 2f16K-6avoC:
66.25
2f16L-6avoC:
17.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_N_BO2N1404_1
(PROTEASOME COMPONENT
PRE3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 11 THR C   1
ALA C  28
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.4A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.05A 2f16N-6avoC:
29.3		 2f16N-6avoC:
21.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
2F16_N_BO2N1404_1
(PROTEASOME COMPONENT
PRE3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 11 THR C   1
LYS C  33
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.63A 2f16N-6avoC:
29.3		 2f16N-6avoC:
21.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
2F16_Y_BO2Y1403_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		7 / 10 THR C   1
ALA C  20
ALA C  22
VAL C  31
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.60A 2f16Y-6avoC:
19.9
2f16Z-6avoC:
24.5		 2f16Y-6avoC:
66.25
2f16Z-6avoC:
17.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_2_BO221405_1
(PROTEASOME COMPONENT
PRE3
PROTEASOME COMPONENT
PUP1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 12 THR C   1
ALA C  28
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.4A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.02A 3mg02-6avoC:
29.2
3mg0V-6avoC:
29.3		 3mg02-6avoC:
21.31
3mg0V-6avoC:
17.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_2_BO221405_1
(PROTEASOME COMPONENT
PRE3
PROTEASOME COMPONENT
PUP1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 12 THR C   1
LYS C  33
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.63A 3mg02-6avoC:
29.2
3mg0V-6avoC:
29.3		 3mg02-6avoC:
21.31
3mg0V-6avoC:
17.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MG0_K_BO2K1402_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 11 THR C   1
ALA C  20
ALA C  28
GLY C  47
ALA C  49
SER C 130
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.4A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
None
 1.07A 3mg0K-6avoC:
34.3
3mg0L-6avoC:
24.9		 3mg0K-6avoC:
66.25
3mg0L-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
3MG0_K_BO2K1402_1
(PROTEASOME COMPONENT
PRE2
PROTEASOME COMPONENT
C5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		7 / 11 THR C   1
ALA C  20
VAL C  31
LYS C  33
GLY C  47
ALA C  49
SER C 130
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
None
 0.61A 3mg0K-6avoC:
34.3
3mg0L-6avoC:
24.9		 3mg0K-6avoC:
66.25
3mg0L-6avoC:
17.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_N_BO2N1404_1
(PROTEASOME COMPONENT
PRE3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 11 THR C   1
ALA C  28
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.4A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.03A 3mg0N-6avoC:
29.3		 3mg0N-6avoC:
21.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3MG0_N_BO2N1404_1
(PROTEASOME COMPONENT
PRE3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 11 THR C   1
LYS C  33
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.62A 3mg0N-6avoC:
29.3		 3mg0N-6avoC:
21.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4LV9_B_20JB601_1
(NICOTINAMIDE
PHOSPHORIBOSYLTRANSF
ERASE)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		4 / 7 ASP C 167
SER C 130
SER C  21
ARG C  19
 None
None
BZ7  C 301 (-4.9A)
None
 1.24A 4lv9A-6avoC:
undetectable
4lv9B-6avoC:
undetectable		 4lv9A-6avoC:
11.13
4lv9B-6avoC:
11.13
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVL_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 11 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.58A 4qvlK-6avoC:
34.2
4qvlL-6avoC:
24.8		 4qvlK-6avoC:
66.25
4qvlL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVL_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 11 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.59A 4qvlY-6avoC:
19.9
4qvlZ-6avoC:
24.6		 4qvlY-6avoC:
66.25
4qvlZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVM_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.50A 4qvmK-6avoC:
34.2
4qvmL-6avoC:
24.8		 4qvmK-6avoC:
65.00
4qvmL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVM_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 10 THR C   1
ALA C  20
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.50A 4qvmY-6avoC:
25.8
4qvmZ-6avoC:
24.5		 4qvmY-6avoC:
65.00
4qvmZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
ALA C  28
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.4A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.12A 4qvnK-6avoC:
34.5
4qvnL-6avoC:
24.8		 4qvnK-6avoC:
65.00
4qvnL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.50A 4qvnK-6avoC:
34.5
4qvnL-6avoC:
24.8		 4qvnK-6avoC:
65.00
4qvnL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
ALA C  28
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.4A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.12A 4qvnY-6avoC:
20.0
4qvnZ-6avoC:
24.6		 4qvnY-6avoC:
65.00
4qvnZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVN_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.50A 4qvnY-6avoC:
20.0
4qvnZ-6avoC:
24.6		 4qvnY-6avoC:
65.00
4qvnZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVP_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 10 THR C   1
ALA C  20
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.49A 4qvpK-6avoC:
34.3
4qvpL-6avoC:
24.5		 4qvpK-6avoC:
65.00
4qvpL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVP_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 10 THR C   1
ALA C  20
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.49A 4qvpY-6avoC:
26.0
4qvpZ-6avoC:
24.6		 4qvpY-6avoC:
65.00
4qvpZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVQ_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
ALA C  28
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.4A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.11A 4qvqK-6avoC:
34.3
4qvqL-6avoC:
24.8		 4qvqK-6avoC:
65.00
4qvqL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVQ_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.51A 4qvqK-6avoC:
34.3
4qvqL-6avoC:
24.8		 4qvqK-6avoC:
65.00
4qvqL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVQ_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
ALA C  28
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.4A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.11A 4qvqY-6avoC:
19.9
4qvqZ-6avoC:
24.5		 4qvqY-6avoC:
65.00
4qvqZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVQ_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.51A 4qvqY-6avoC:
19.9
4qvqZ-6avoC:
24.5		 4qvqY-6avoC:
65.00
4qvqZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVV_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		4 / 8 THR C   1
LYS C  33
MET C  45
GLY C  47
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
 0.53A 4qvvK-6avoC:
33.9
4qvvL-6avoC:
24.8		 4qvvK-6avoC:
65.00
4qvvL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVV_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		4 / 8 THR C   1
LYS C  33
MET C  45
GLY C  47
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
 0.52A 4qvvY-6avoC:
19.6
4qvvZ-6avoC:
24.5		 4qvvY-6avoC:
65.00
4qvvZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVW_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 11 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
 0.60A 4qvwK-6avoC:
34.2
4qvwL-6avoC:
24.8		 4qvwK-6avoC:
65.00
4qvwL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVW_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 11 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
 0.61A 4qvwY-6avoC:
19.8
4qvwZ-6avoC:
24.6		 4qvwY-6avoC:
65.00
4qvwZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVY_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 10 ALA C  20
ALA C  22
VAL C  31
LYS C  33
GLY C  47
 BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
 1.03A 4qvyK-6avoC:
33.9
4qvyL-6avoC:
24.8		 4qvyK-6avoC:
65.00
4qvyL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVY_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 10 THR C   1
ALA C  20
ALA C  22
VAL C  31
LYS C  33
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
 0.60A 4qvyK-6avoC:
33.9
4qvyL-6avoC:
24.8		 4qvyK-6avoC:
65.00
4qvyL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVY_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 10 ALA C  20
ALA C  22
VAL C  31
LYS C  33
GLY C  47
 BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
 1.03A 4qvyY-6avoC:
25.6
4qvyZ-6avoC:
24.5		 4qvyY-6avoC:
65.00
4qvyZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QVY_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 10 THR C   1
ALA C  20
ALA C  22
VAL C  31
LYS C  33
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
 0.61A 4qvyY-6avoC:
25.6
4qvyZ-6avoC:
24.5		 4qvyY-6avoC:
65.00
4qvyZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW0_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 7 THR C   1
ALA C  20
ALA C  22
LYS C  33
MET C  45
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
 0.63A 4qw0K-6avoC:
33.7		 4qw0K-6avoC:
63.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW0_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 7 THR C   1
ALA C  20
ALA C  22
LYS C  33
MET C  45
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
 0.63A 4qw0Y-6avoC:
19.5		 4qw0Y-6avoC:
63.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW1_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 11 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.54A 4qw1K-6avoC:
34.3
4qw1L-6avoC:
24.9		 4qw1K-6avoC:
65.00
4qw1L-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW1_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 10 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.55A 4qw1Y-6avoC:
19.9
4qw1Z-6avoC:
24.6		 4qw1Y-6avoC:
65.00
4qw1Z-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 10 THR C   1
ALA C  20
ALA C  28
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.4A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.23A 4qw3K-6avoC:
33.9
4qw3L-6avoC:
24.7		 4qw3K-6avoC:
65.00
4qw3L-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 10 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.58A 4qw3K-6avoC:
33.9
4qw3L-6avoC:
24.7		 4qw3K-6avoC:
65.00
4qw3L-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 10 THR C   1
ALA C  20
ALA C  28
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.4A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.23A 4qw3Y-6avoC:
19.7
4qw3Z-6avoC:
24.4		 4qw3Y-6avoC:
65.00
4qw3Z-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QW3_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 10 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.58A 4qw3Y-6avoC:
19.7
4qw3Z-6avoC:
24.4		 4qw3Y-6avoC:
65.00
4qw3Z-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QWU_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
ALA C  28
MET C  45
GLY C  47
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.4A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
 1.06A 4qwuK-6avoC:
33.3
4qwuL-6avoC:
24.6		 4qwuK-6avoC:
65.00
4qwuL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QWU_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
 0.54A 4qwuK-6avoC:
33.3
4qwuL-6avoC:
24.6		 4qwuK-6avoC:
65.00
4qwuL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QWU_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
ALA C  28
MET C  45
GLY C  47
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.4A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
 1.08A 4qwuY-6avoC:
19.6
4qwuZ-6avoC:
24.7		 4qwuY-6avoC:
65.00
4qwuZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
4QWU_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 9 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
 0.53A 4qwuY-6avoC:
19.6
4qwuZ-6avoC:
24.7		 4qwuY-6avoC:
65.00
4qwuZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BXN_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 11 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.60A 5bxnK-6avoC:
34.4
5bxnL-6avoC:
24.5		 5bxnK-6avoC:
66.25
5bxnL-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5BXN_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 11 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.61A 5bxnY-6avoC:
20.0
5bxnZ-6avoC:
24.5		 5bxnY-6avoC:
66.25
5bxnZ-6avoC:
17.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5F_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 9 THR C   1
SER C  21
SER C  27
VAL C  31
MET C  45
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-4.9A)
BZ7  C 301 (-3.4A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-2.8A)
 0.75A 5l5fK-6avoC:
34.5
5l5fL-6avoC:
24.5		 5l5fK-6avoC:
100.00
5l5fL-6avoC:
14.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5F_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 9 THR C   1
SER C  21
VAL C  31
LYS C  33
MET C  45
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-4.9A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-2.8A)
 0.66A 5l5fK-6avoC:
34.5
5l5fL-6avoC:
24.5		 5l5fK-6avoC:
100.00
5l5fL-6avoC:
14.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5F_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 8 THR C   1
SER C  21
LYS C  33
MET C  45
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-4.9A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-2.8A)
 0.59A 5l5fY-6avoC:
34.5
5l5fZ-6avoC:
24.6		 5l5fY-6avoC:
100.00
5l5fZ-6avoC:
14.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5F_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 8 THR C   1
SER C  21
SER C  27
MET C  45
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-4.9A)
BZ7  C 301 (-3.4A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-2.8A)
 0.69A 5l5fY-6avoC:
34.5
5l5fZ-6avoC:
24.6		 5l5fY-6avoC:
100.00
5l5fZ-6avoC:
14.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L5Z_B_BO2B201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 12 THR C   1
LYS C  33
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.62A 5l5zV-6avoC:
29.4
5l5zb-6avoC:
29.3		 5l5zV-6avoC:
17.24
5l5zb-6avoC:
21.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5Z_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA
TYPE-5,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 9 THR C   1
ALA C  20
ALA C  22
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.65A 5l5zK-6avoC:
34.4
5l5zL-6avoC:
24.5		 5l5zK-6avoC:
75.00
5l5zL-6avoC:
14.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5L5Z_N_BO2N201_1
(PROTEASOME SUBUNIT
BETA TYPE-2
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 12 THR C   1
LYS C  33
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.62A 5l5zH-6avoC:
27.5
5l5zN-6avoC:
29.3		 5l5zH-6avoC:
17.24
5l5zN-6avoC:
21.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L5Z_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA
TYPE-5,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 9 THR C   1
ALA C  20
ALA C  22
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.66A 5l5zY-6avoC:
34.4
5l5zZ-6avoC:
24.6		 5l5zY-6avoC:
75.00
5l5zZ-6avoC:
14.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L66_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 10 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.55A 5l66K-6avoC:
34.7
5l66L-6avoC:
24.8		 5l66K-6avoC:
95.00
5l66L-6avoC:
14.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L66_K_BO2K301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 10 THR C   1
SER C  27
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.4A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.60A 5l66K-6avoC:
34.7
5l66L-6avoC:
24.8		 5l66K-6avoC:
95.00
5l66L-6avoC:
14.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L66_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 10 THR C   1
ALA C  20
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.54A 5l66Y-6avoC:
34.7
5l66Z-6avoC:
24.6		 5l66Y-6avoC:
95.00
5l66Z-6avoC:
14.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5L66_Y_BO2Y301_1
(PROTEASOME SUBUNIT
BETA
TYPE-8,PROTEASOME
SUBUNIT BETA TYPE-5
PROTEASOME SUBUNIT
BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA
TYPE-6,PROTEASOME
SUBUNIT BETA
TYPE-1,PROTEASOME
SUBUNIT BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 10 THR C   1
SER C  27
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.4A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.61A 5l66Y-6avoC:
34.7
5l66Z-6avoC:
24.6		 5l66Y-6avoC:
95.00
5l66Z-6avoC:
14.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF3_B_BO2B305_1
(PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 12 THR C   1
LYS C  33
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.64A 5lf3b-6avoC:
28.8		 5lf3b-6avoC:
20.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5LF3_K_BO2K305_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		8 / 11 THR C   1
ALA C  20
ALA C  22
LYS C  33
MET C  45
GLY C  47
ALA C  49
TYR C 169
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
None
 0.75A 5lf3K-6avoC:
35.4
5lf3L-6avoC:
25.9		 5lf3K-6avoC:
75.00
5lf3L-6avoC:
15.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF3_N_BO2N304_1
(PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 12 THR C   1
LYS C  33
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.64A 5lf3N-6avoC:
28.8		 5lf3N-6avoC:
20.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF3_V_BO2V303_1
(PROTEASOME SUBUNIT
BETA TYPE-7
PROTEASOME SUBUNIT
BETA TYPE-3)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 10 THR C   1
ALA C  20
LYS C  33
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.44A 5lf3V-6avoC:
30.1
5lf3W-6avoC:
26.6		 5lf3V-6avoC:
16.24
5lf3W-6avoC:
15.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
5LF3_Y_BO2Y305_1
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-1)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		8 / 11 THR C   1
ALA C  20
ALA C  22
LYS C  33
MET C  45
GLY C  47
ALA C  49
TYR C 169
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
None
 0.74A 5lf3Y-6avoC:
35.4
5lf3Z-6avoC:
25.8		 5lf3Y-6avoC:
75.00
5lf3Z-6avoC:
15.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_B_6V8B304_0
(PROTEASOME SUBUNIT
BETA TYPE-6
PROTEASOME SUBUNIT
BETA TYPE-7)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 12 THR C   1
ALA C  28
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.4A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.02A 5lf7V-6avoC:
30.1
5lf7b-6avoC:
28.8		 5lf7V-6avoC:
undetectable
5lf7b-6avoC:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_B_6V8B304_0
(PROTEASOME SUBUNIT
BETA TYPE-6
PROTEASOME SUBUNIT
BETA TYPE-7)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 12 THR C   1
LYS C  33
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.68A 5lf7V-6avoC:
30.1
5lf7b-6avoC:
28.8		 5lf7V-6avoC:
undetectable
5lf7b-6avoC:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_K_6V8K305_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 11 ALA C  20
ALA C  22
VAL C  31
LYS C  33
MET C  45
GLY C  47
 BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
 1.10A 5lf7K-6avoC:
35.4
5lf7L-6avoC:
25.9		 5lf7K-6avoC:
undetectable
5lf7L-6avoC:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_K_6V8K305_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		8 / 11 THR C   1
ALA C  20
ALA C  22
VAL C  31
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.68A 5lf7K-6avoC:
35.4
5lf7L-6avoC:
25.9		 5lf7K-6avoC:
undetectable
5lf7L-6avoC:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_N_6V8N305_0
(PROTEASOME SUBUNIT
BETA TYPE-6
PROTEASOME SUBUNIT
BETA TYPE-7)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 12 THR C   1
ALA C  28
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.4A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.02A 5lf7H-6avoC:
30.2
5lf7N-6avoC:
28.8		 5lf7H-6avoC:
undetectable
5lf7N-6avoC:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_N_6V8N305_0
(PROTEASOME SUBUNIT
BETA TYPE-6
PROTEASOME SUBUNIT
BETA TYPE-7)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		5 / 12 THR C   1
LYS C  33
SER C  46
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 ( 4.8A)
None
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.67A 5lf7H-6avoC:
30.2
5lf7N-6avoC:
28.8		 5lf7H-6avoC:
undetectable
5lf7N-6avoC:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_Y_6V8Y306_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 11 ALA C  20
ALA C  22
VAL C  31
LYS C  33
MET C  45
GLY C  47
 BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
 1.07A 5lf7Y-6avoC:
35.5
5lf7Z-6avoC:
25.9		 5lf7Y-6avoC:
undetectable
5lf7Z-6avoC:
undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5LF7_Y_6V8Y306_0
(PROTEASOME SUBUNIT
BETA TYPE-1
PROTEASOME SUBUNIT
BETA TYPE-5)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		8 / 11 THR C   1
ALA C  20
ALA C  22
VAL C  31
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.66A 5lf7Y-6avoC:
35.5
5lf7Z-6avoC:
25.9		 5lf7Y-6avoC:
undetectable
5lf7Z-6avoC:
undetectable
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_K_BO2K301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		7 / 11 THR C   1
ALA C  20
ALA C  22
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.64A 6hwdK-6avoC:
34.6
6hwdL-6avoC:
24.9		 6hwdK-6avoC:
66.25
6hwdL-6avoC:
21.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_K_BO2K301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 11 THR C   1
ALA C  20
ALA C  28
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.4A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.21A 6hwdK-6avoC:
34.6
6hwdL-6avoC:
24.9		 6hwdK-6avoC:
66.25
6hwdL-6avoC:
21.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_Y_BO2Y301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		7 / 11 THR C   1
ALA C  20
ALA C  22
LYS C  33
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.5A)
BZ7  C 301 ( 4.8A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 0.63A 6hwdY-6avoC:
20.2
6hwdZ-6avoC:
24.6		 6hwdY-6avoC:
66.25
6hwdZ-6avoC:
21.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.
6HWD_Y_BO2Y301_0
(PROTEASOME SUBUNIT
BETA TYPE-5
PROTEASOME SUBUNIT
BETA TYPE-6)		 6avo PROTEASOME SUBUNIT
BETA TYPE-8
(Homo
sapiens) 		6 / 11 THR C   1
ALA C  20
ALA C  28
MET C  45
GLY C  47
ALA C  49
 BZ7  C 301 (-4.0A)
BZ7  C 301 (-3.5A)
BZ7  C 301 (-3.4A)
BZ7  C 301 ( 4.7A)
BZ7  C 301 (-4.5A)
BZ7  C 301 (-2.8A)
 1.21A 6hwdY-6avoC:
20.2
6hwdZ-6avoC:
24.6		 6hwdY-6avoC:
66.25
6hwdZ-6avoC:
21.35